Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: Recombinant is better

Blood Transfusion

Volumn 8, Issue 4, 2010, Pages 292-296

  Franchini, Massimo ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

CLINICAL TRIAL; ENDOCYTOSIS; HEMOPHILIA; HUMAN; IMMUNOGENICITY; LIFE EXPECTANCY; META ANALYSIS; PATIENT SAFETY; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW;

FACTOR VIII; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS;

EID: 78049271862     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2010.0067-10     Document Type: Review

References (48)

1. Franchini M, Coppola A, Molinari AC, et al. Forum on: the role of recombinant factor VIII in children with severe haemophilia A. Haemophilia 2009; 15: 578-86.
2. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
3. White GC 2nd, McMillan CW, Kingdon HS, Shoemaker CB. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989; 320: 166-70.
4. Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with haemophilia. Thromb Haemost 2009; 101: 674-81.
5. Franchini M, Lippi G. Recombinant factor VIII concentrates. Semin Thromb Hemost 2010; 36: 493-7.
6. Tagliaferri A, Rivolta GF, Iorio A, et al. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16: 437-46.
7. Leissinger CA. Prophylaxis in haemophilia patients with inhibitors. Haemophilia 2006; 12(Suppl 6): 67-73.
8. Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008; 14(Suppl 3): 10-8.
9. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-21.
10. Pipe SW. Recombinant clotting factors. Thromb Haemost 2008; 99: 840-50.
11. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63. (Pubitemid 37193570)
12. Gomperts ED. The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors. Haemophilia 2006; 12: 573-8.
13. Astermark J. Overview of inhibitors. Semin Hematol 2006; 43 (2 Suppl 4):S3-7.
14. Briet E, Rosendaal FR, Kreuz W, et al. High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products. Thromb Haemost 1994; 72: 162-4.
15. Chambost H. Assessing risk factors: prevention of inhibitors in haemophilia. Haemophilia 2010; 16(Suppl 2): 10-5.
16. Ettingshausen CE, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006; 12(Suppl 6): 102-6.
17. Goodeve A. The incidence of inhibitor development according to specific mutations -and treatment? Blood Coagul Fibrinolysis 2003; 14(Suppl 1): S17-21.
18. Hay CR. The epidemiology of factor VIII inhibitors. Haemophilia 2006; 12(Suppl 6): 23-9.
19. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12(Suppl 6): 15-22.
20. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 5: 145-54. (Pubitemid 29326763)
21. Scharrer I, Neutzling O. Incidence of inhibitors in haemophiliacs. A review of the literature. Blood Coagul Fibrinolysis 1993; 4: 753-8.
22. Scharrer I, Neutzling O, Schwaab R, et al. Experiences with recombinant factor VIII products: development of inhibitors and immune tolerance therapy. Ann Hematol 1998; 76(Suppl 1): A1-6.
23. Franchini M, Lippi G. VWF-containing FVIII concentrates and inhibitors in hemophilia A: a critical literature review. Thromb Haemost 2010.
24. Verbruggen B, van Heerde W, Budde U. Methodological shortcomings in assessment of factor VIII concentrate inhibition. Haemophilia 2007; 13: 680-1.
25. Dasgupta S, Repesse Y, Bayry J, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-2.
26. Pfistershammer K, Stockl J, Siekmann J, et al. Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells. Thromb Haemost 2006; 96: 309-16.
27. Kreuz W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost 2002; 28: 285-90. (Pubitemid 34634343)
28. Mauser-Bunschoten EP, van der Bom JG, Bongers M, et al. Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A. Haemophilia 2001; 7: 364-8. (Pubitemid 32677654)
29. Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
30. Chalmers EA, Brown SA, Keeling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13: 149-55.
31. Gouw SC, van der Bom JG, Auerswald G, et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-7. (Pubitemid 46827760)
32. Kreuz W, Auerswald G, Budde U, et al. Inhibitor incidence in previously untreated patients (PUPs) with hemophilia A and B. A prospective multicenter study of the pediatric study group of the German, Swiss and Austrian Society of Thrombosis and Hemostasis (GTH). The GTH-PUP-Study Group. In: Scharrer I, Schramm W, eds. 35th Hemophilia Symposium. New York, NY: Springer Berlin Heidelberg; 2006:34-7.
33. Addiego JE Jr, Gomperts E, Liu SL, et al. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography. Thromb Haemost 1992; 67: 19-27.
34. Kreuz W, Gill JC, Rothschild C, et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost 2005; 93: 457-67. (Pubitemid 40392533)
35. Musso R, Santagostino E, Faradji A, et al. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Thromb Haemost 2008; 99: 52-8.
36. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35. (Pubitemid 36874391)
37. Scharrer I, Ehrlich HJ. Reported inhibitor incidence in FVIII PUP studies: comparing apples with oranges? Haemophilia 2004; 10: 197-8.
38. Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously-untreated hemophilia a patients treated with plasma-derived or recombinant factor VIII concentrates. A systematic review. J Thromb Haemost 2010:[Epub ahead of print].
39. Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19: 139-48. (Pubitemid 28438925)
40. Berntorp E, Nilsson IM. Immune tolerance and the immune modulation protocol. Vox Sang 1996; 70(Suppl 1): 36-41.
41. Sukhu K, Keeling DM, Giangrande PL. Variation in inhibitor reactivity in acquired haemophilia A with different concentrates. Clin Lab Haematol 2000; 22: 287-90. (Pubitemid 32047103)
42. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88: EREP05.
43. Orsini F, Rotschild C, Beurrier P, et al. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica. 2005; 90: 1288-90.
44. Greninger DA, Saint-Remy JM, Jacquemin M, et al. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia 2007; 14: 295-302. (Pubitemid 351338690)
45. Kurth MA, Dimichele D, Sexauer C, et al. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2007; 14: 50-55.
46. Gringeri A, Musso R, Mazzucconi MG, et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13: 373-9.
47. Dimichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl 1): 1-22.
48. Dimichele DM, Goldberg I, Foulkes M, on behalf of the International Immune Tolerance Study Group. International prospective randomized immune tolerance (ITI) study: preliminary results of therapeutic efficacy and safety [abstract 07S03]. Haemophilia 2010; 16(Suppl 4): 29.